The GLP-1 Side Effect Nobody’s Warning You About.

Muscle loss is getting some attention. But what's happening to the gut? SIBO, dysbiosis, and gastroparesis may be the real story nobody is telling.

By Amanda, BSc Exercise Science | Prime Choice Club

The GLP-1 drug conversation has finally started including muscle loss. Good. That matters to men and women over 35 using a GLP-1 and your lifestyle strategy should incorporate resistance training to minimize the loss. But the side effect I am most concerned about, the one that I think carries the most serious long-term health consequences for the largest number of users, is barely being discussed anywhere.
It's the gut.

Specifically: what GLP-1 receptor agonists do to gastric motility, to the migrating motor complex, to the intestinal microbiome, and to the conditions that allow SIBO, small intestinal bacterial overgrowth, and gut dysbiosis to take hold and progressively worsen. This is the conversation that is almost entirely absent from mainstream coverage of these drugs, and it's the one I think people most urgently need to have before making this decision.

Because here's the thing about gut damage. It doesn't just make you uncomfortable. It can stop you from losing weight entirely. It can make you profoundly sick in ways that mimic dozens of other conditions. And it can take years to resolve, long after you've stopped the drug that caused it, if you know what caused it at all.

WHAT GLP-1 DRUGS ACTUALLY DO TO THE GUT

To understand the gut risk, you need to understand how these drugs work at the mechanical level. GLP-1 receptor agonists don't just suppress appetite centrally in the brain. They act on GLP-1 receptors throughout the entire gastrointestinal tract, producing profound changes to gut motility, gastric acid secretion, and the coordinated muscular activity that moves food through the digestive system.

The primary mechanism of their weight loss effect is slowing gastric emptying: food stays in the stomach significantly longer than it normally would. This is intentional. Keeping food in the stomach longer produces a sustained feeling of fullness. It reduces appetite. It lowers post-meal blood sugar spikes. For the purposes of weight loss, it works.

But the gastrointestinal system is not a passive tube. It is a highly coordinated muscular organ system with its own nervous system, the enteric nervous system, often called the second brain, and a carefully timed series of motility patterns that do far more than move food from one end to the other. When you significantly and chronically alter gastric motility with a pharmacological agent, the downstream consequences extend well beyond the stomach.

 

THE MIGRATING MOTOR COMPLEX: THE GUT'S HOUSEKEEPING SYSTEM

This is the piece of the puzzle that most GLP-1 users have never heard of, and it's so important to understand why these drugs carry a genuine SIBO risk.

The migrating motor complex, or MMC, is a series of rhythmic muscular contractions that sweep through the stomach and small intestine approximately every 90 to 120 minutes during fasting states. Gastroenterologists call it the interdigestive housekeeper. Its job is to physically sweep bacteria, undigested food particles, cellular debris, and anything else that shouldn't be sitting in the small intestine down into the large intestine where bacteria belong. It only operates between meals, during the fasting windows when the digestive system is not actively processing food.

The small intestine is supposed to be relatively sterile compared to the large intestine. The reason it stays that way under normal conditions is partly the MMC doing its sweeping work between meals, and partly the acidity of gastric juices and the speed of intestinal transit maintaining an environment where bacteria cannot easily proliferate.

GLP-1 receptor agonists disrupt both of these protective mechanisms simultaneously. They slow gastric emptying, which means the stomach is never truly empty, which means the MMC cannot fully activate because the fasting signal that triggers it is impaired. And they reduce gastric acid secretion, which reduces one of the primary barriers against bacterial proliferation in the upper GI tract. Food sits in the stomach and small intestine longer. Bacterial migration upward from the colon faces reduced resistance. The conditions for small intestinal bacterial overgrowth are created not as a side effect but as a direct consequence of the drug's intended mechanism.

SIBO occurs when bacteria that belong in the large intestine colonize the small intestine in excessive numbers. The consequences are not minor. Bloating, gas, and abdominal distension that can be severe. Diarrhea or constipation depending on the bacterial profile. Malabsorption of nutrients including fat-soluble vitamins, B12, and iron, producing deficiencies that compound over time. Systemic inflammation from bacterial endotoxins crossing the compromised intestinal lining into circulation. And critically for anyone taking these drugs for weight loss: impaired nutrient absorption and chronic gut inflammation that makes weight management paradoxically harder, not easier. You can be on a drug designed to help you lose weight while your gut is simultaneously working against you through SIBO-driven metabolic dysfunction.

 

GASTROPARESIS: THE SERIOUS END OF THE SPECTRUM

Beyond SIBO risk, there is a more severe gut motility consequence that has generated significant legal and regulatory attention: gastroparesis. This is a condition where the stomach muscles are partially or fully paralyzed, preventing normal emptying. Food sits in the stomach for extended periods, causing severe nausea, vomiting, abdominal pain, and malnutrition.

In 2023 the FDA received thousands of adverse event reports linking semaglutide and related GLP-1 drugs to gastroparesis symptoms. A 2023 study published in JAMA noted that GLP-1 receptor agonists were associated with a significantly increased risk of gastroparesis compared to controls in a large retrospective analysis. Multiple class action lawsuits were filed against Novo Nordisk and Eli Lilly specifically citing gastroparesis as an undisclosed risk. In the same year anesthesiologists began issuing formal guidance advising patients on GLP-1 drugs to disclose this before surgery, because the delayed gastric emptying creates a serious aspiration risk under general anesthesia, even after the standard pre-operative fasting period.

Gastroparesis is not easily reversible. It can persist long after the drug causing it is discontinued, in some cases permanently, because the enteric nervous system damage that produces impaired motility can be progressive. The people most at risk are those who were already predisposed to motility issues, people with a history of digestive problems, those with undiagnosed diabetes-related gastroparesis, or those with prior gut dysbiosis. Many of these are exactly the people seeking GLP-1 drugs for weight and metabolic management.

THE GUT DYSBIOSIS PICTURE

Beyond SIBO specifically, emerging research is documenting broader gut microbiome disruption associated with GLP-1 drug use. The gut microbiome is extraordinarily sensitive to changes in intestinal transit time, gastric acid availability, and the nutrient environment that reaches the colon. GLP-1 drugs change all three.

A healthy gut microbiome is directly associated with healthy weight management, good insulin sensitivity, regulated appetite, stable mood, and immune function. Research by Zhao et al. published in Science in 2018 established that specific beneficial gut bacteria mediate a significant portion of the metabolic benefits of dietary intervention. Research on GLP-1 drugs and the microbiome is early but directionally concerning: the motility disruption, reduced gastric acid, altered nutrient delivery, and the inflammatory consequences of SIBO all create conditions where beneficial bacteria lose ground to pathogenic and opportunistic species.

The gut-weight connection matters here enormously. People with disrupted microbiomes characterized by low diversity and overgrowth of certain species have been shown to extract more calories from food, have higher inflammatory markers, and have worse insulin sensitivity than people with healthy, diverse microbiomes. If GLP-1 drugs are disrupting the microbiome in ways that worsen this profile, they may be undermining the very metabolic environment that weight loss and maintenance depend on, while simultaneously appearing to produce results through appetite suppression. The long-term metabolic consequence may not show up until after the drug is stopped and the weight returns, this time with a more damaged gut making recovery harder.

And gut damage takes time to fix. Real time. GI-MAP testing, targeted antimicrobials, binders, probiotics, and gut restoration protocols can take months to years to fully resolve established dysbiosis. The longer the gut has been disrupted, the more entrenched the bacterial patterns become and the longer the healing takes. This is why I consider the gut risk of GLP-1 drugs the most serious and most under-discussed risk of all: it's the one that keeps making you sick long after you've stopped the drug, and most people never connect the symptoms to the original cause.

THE OTHER SIDE EFFECTS WORTH KNOWING

With the gut picture now in context, the other documented GLP-1 side effects make even more sense as part of a connected pattern:

Muscle and lean mass loss

Research published in Diabetes, Obesity and Metabolism has documented that between 25 and 40% of weight lost on GLP-1 drugs comes from lean mass including muscle. This is the side effect getting some social media attention. It matters: muscle loss reduces metabolic rate, impairs glucose disposal, accelerates aging, and makes weight regain more likely upon stopping. For anyone over 35 where sarcopenia is already beginning, losing significant muscle to a weight loss drug is a poor trade.

Gallbladder disease: stones, stasis, and inflammation
This is documented in the clinical trials and barely discussed publicly. GLP-1 receptors are expressed in the gallbladder wall, and GLP-1 agonists reduce gallbladder motility just as they reduce gastric motility. The result is bile stasis: bile sitting in the gallbladder longer than it should, concentrating, and forming cholesterol crystals and gallstones. In the STEP 1 semaglutide trial, cholelithiasis (gallstones) occurred in 1.6% of semaglutide users versus 0.7% in placebo. Cholecystitis (gallbladder inflammation) occurred at double the rate of placebo. Rapid weight loss itself is an independent risk factor for gallstones, so GLP-1 users face a double exposure: the drug's direct effect on gallbladder motility compounded by the rapid weight loss it produces. This matters far beyond the gallbladder itself, as the next two points explain.

Thyroid suppression: the function concern beyond the cancer warning
GLP-1 receptors are expressed on thyroid C-cells, producing the well-known black box warning for medullary thyroid carcinoma. But the broader thyroid function concern extends significantly beyond the cancer risk. Slowed gastric emptying reduces the absorption of the micronutrients most critical for thyroid hormone production and conversion including zinc, selenium, and iodine. Additionally the gut dysbiosis produced by GLP-1-induced motility disruption directly impairs T4 to T3 conversion: approximately 20% of this conversion occurs in the gut via bacteria-dependent deiodinase activity. Lower T3 means a lower metabolic rate. This compounds the muscle loss-driven metabolic suppression and the liver's capacity to clear hormones efficiently, setting up the hormonal cascade described below.

Estrogen dominance: the downstream hormonal consequence nobody is connecting
This is the most underreported long-term consequence of GLP-1 use, and it follows directly from the gut dysbiosis and gallbladder impairment already discussed. Your body clears estrogen through two primary pathways: hepatic conjugation followed by excretion through bile into the intestine, and intestinal metabolism by the estrobolome, the collection of gut bacteria responsible for processing estrogens before excretion. When GLP-1 drugs impair gallbladder motility and bile flow, the biliary estrogen clearance pathway is compromised. When GLP-1 drugs produce gut dysbiosis and SIBO, the estrobolome is disrupted, allowing bacteria that produce beta-glucuronidase to proliferate. Beta-glucuronidase is the enzyme that deconjugates estrogen that has already been tagged by the liver for excretion, freeing it to be reabsorbed through the intestinal wall and recirculated rather than eliminated. The result is elevated circulating estrogen not from increased production but from impaired clearance at both the biliary and intestinal level. Combined with the muscle loss that reduces testosterone, and the reduced progesterone that follows thyroid suppression and metabolic stress, chronic GLP-1 use creates a hormonal environment of elevated tissue estrogen with depleted protective hormones. In Ray Peat's framework this is the most damaging hormonal state: high tissue estrogen, low progesterone, suppressed thyroid, reduced androgens. This cascade makes body composition management harder, sleep worse, mood more volatile, and the weight regain after stopping the drug faster and more difficult to reverse. And estrobolome disruption is not quickly corrected. Restoring the beneficial bacteria requires resolving the SIBO, which as already noted can take months to years.

Nausea, vomiting, and GI distress
Documented in the STEP 1 semaglutide trial at 44% for nausea and 24.8% for vomiting. In many cases this is not merely a tolerated side effect but the primary mechanism of caloric reduction: eating less because eating feels unpleasant. The GI distress is not independent of the gut motility disruption discussed above. It is a symptom of the same underlying enteric nervous system changes.

Rebound weight gain and dependency
A 2022 study published in Diabetes, Obesity and Metabolism found that most participants regained the majority of lost weight within one year of stopping semaglutide. With diminished muscle mass, a disrupted microbiome, impaired thyroid T4-to-T3 conversion, and estrogen dominance from compromised biliary and gut estrogen clearance, the person stopping a GLP-1 drug is metabolically and hormonally worse positioned for weight management than before they started. The drug treated the symptom. The underlying drivers were untouched. And several mechanisms, particularly the gut and hormonal environment, may be actively worse.

Cost
Approximately $1,000 to $1,300 per month without insurance coverage. Given the rebound data and the potential need for significant gut restoration after cessation, the total cost picture is substantial.

THE NATURAL APPROACH: ADDRESSING THE CAUSE, NOT THE SYMPTOM

GLP-1 drugs are a solution to a specific problem: dysregulated appetite and satiety signals in a metabolic environment that is defending excess weight. They address the symptom directly and powerfully. What they don't address, and what their gut side effects may actually worsen, is the underlying biology driving the dysregulation in the first place.

Blood sugar instability driving cortisol and hunger cycles. Serotonin imbalance driving compulsive and emotional eating. Insulin resistance making the body defend fat stores. Gut dysbiosis itself producing the inflammation and metabolic disruption that impairs weight regulation. Chronic stress and poor sleep dysregulating the entire hormonal system. These are the root causes. And addressing them produces durable results without the gut damage, without the muscle loss, without the dependency, and without the $1,000 monthly price tag.

This is where saffron becomes a genuinely compelling part of a real solution. Not because it mimics the pharmacological mechanism of a GLP-1 drug. But because it addresses one of the primary root causes of dysregulated appetite: serotonin, the neurotransmitter whose deficit drives the compulsive, emotional, reward-seeking eating that caloric restriction and appetite suppression alone never fully resolve.

WHY SAFFRON: THE RESEARCH BEHIND THE MOST EXPENSIVE SPICE IN THE WORLD

Saffron (Crocus sativus) has been used medicinally for over 3,500 years across Persian, Greek, Roman, and Ayurvedic traditions. Its modern research profile is extraordinary for a botanical, with over 40 clinical trials published in the past two decades documenting its effects on mood, appetite, cognitive function, and metabolic health.

The two primary active compounds are crocin and safranal. Crocin is the carotenoid pigment responsible for saffron's characteristic golden color and contributes to its antioxidant and anti-inflammatory effects. Safranal is a volatile compound responsible for the distinctive aroma and contributes to saffron's neurological effects. Together they produce a range of biological actions through a mechanism that is directly relevant to the appetite and emotional eating picture.

THE SEROTONIN CONNECTION: APPETITE IS NOT JUST ABOUT HUNGER

This is the most important thing to understand about saffron, and about appetite regulation more broadly. There are two fundamentally different reasons people eat: physical hunger, which is the genuine metabolic signal that the body needs fuel, and appetite, which includes the emotional, reward-seeking, and habit-driven eating that occurs independently of physical need.

Physical hunger is regulated primarily by ghrelin, leptin, and blood sugar signals. Appetite, particularly the compulsive snacking and between-meal eating that drives most excess caloric intake in non-obese adults, is regulated significantly by serotonin. Low serotonin is strongly associated with increased reward-seeking food behavior, carbohydrate and sugar cravings, emotional eating, and the inability to feel satisfied after eating. This is why depression and anxiety, both of which involve serotonin dysregulation, are so consistently associated with overeating and weight gain.

GLP-1 drugs address hunger by slowing gastric emptying and suppressing the ghrelin-driven hunger signal. They have minimal effect on the serotonin-driven appetite and emotional eating component.

Saffron directly modulates serotonin through a mechanism similar to selective serotonin reuptake inhibitors (SSRIs): it inhibits serotonin reuptake in the synaptic cleft, increasing the availability of serotonin at receptor sites. Multiple clinical trials have validated saffron's efficacy as an antidepressant comparable to pharmaceutical SSRIs. And the appetite research directly confirms the downstream effect.

A landmark randomized double-blind placebo-controlled trial published in Nutrition Research by Gout et al. in 2010 found that saffron extract supplementation significantly reduced snacking behavior and increased feelings of satiety in mildly overweight women over eight weeks. The placebo group showed no change in snacking frequency. The saffron group showed a 55% reduction in snacking episodes compared to baseline. Body weight and BMI decreased significantly in the saffron group. The mechanism identified: improved serotonin signaling reducing the reward-seeking, mood-driven snacking that is distinct from genuine hunger.

 

This is the appetite control mechanism that GLP-1 drugs don't address. Making you feel physically full doesn't stop emotional eating. Improving serotonin signaling does.

SAFFRON'S ADDITIONAL MECHANISMS RELEVANT TO WEIGHT AND METABOLISM

Beyond serotonin and appetite, saffron has documented effects on several other mechanisms relevant to the weight and metabolic health picture:

Blood sugar regulation: a systematic review and meta-analysis published in Phytotherapy Research confirmed that saffron supplementation produced significant improvements in fasting blood glucose and insulin sensitivity across multiple randomized controlled trials. The proposed mechanisms include crocin's effects on glucose transporter expression and safranal's anti-inflammatory activity reducing insulin receptor suppression. In the context of everything we've covered in the blood sugar series, a botanical that directly supports insulin sensitivity while also addressing the serotonin-driven eating patterns that destabilize blood sugar is addressing both ends of the metabolic equation simultaneously.

Anti-inflammatory activity: crocin and safranal have documented anti-inflammatory effects through inhibition of NF-kB signaling and reduction of inflammatory cytokines including TNF-alpha and IL-6. Chronic inflammation is a primary driver of insulin resistance, leptin resistance, and the hormonal dysregulation that makes weight management harder. Reducing the inflammatory load directly supports the metabolic environment where healthy weight regulation is possible.

Cortisol modulation: research has documented saffron's anxiolytic effects, reducing perceived stress and anxiety markers. Given the blood sugar and weight connection to cortisol that we've covered throughout this series, a compound that reduces anxiety and stress response is also indirectly supporting the hormonal environment that prevents cortisol-driven fat storage and hunger dysregulation.

Antioxidant protection: saffron contains some of the most potent antioxidant carotenoids available, protecting mitochondrial function from the oxidative stress that impairs cellular energy metabolism. In Peat's framework, supporting mitochondrial function supports thyroid-driven metabolic rate, which is the foundation of sustainable body composition management.

BUILDING THE BODY YOU WANT WITHOUT LOSING THE MUSCLE YOU NEED

Here is where the full protocol comes together, because saffron alone is a tool, not a complete strategy. The complete strategy is the one that addresses every dimension of sustainable body composition: appetite regulation, metabolic rate, muscle building, blood sugar stability, and hormonal health.

The central principle from the pro-metabolic framework is this: sustainable leanness comes from a high-functioning metabolism supported by adequate muscle mass, not from a suppressed metabolism created by severe caloric restriction or pharmacological appetite suppression. Lose muscle to lose weight and you've damaged your metabolic rate for the long term. Build muscle while losing fat and you've improved it.

The appetite and cravings layer: Prime Choice Saffron taken twice daily provides 177mg of Crocus sativus extract per day, in line with the clinical doses used in research showing appetite control and mood benefits. Take one capsule in the morning to support satiety and serotonin tone through the day, and one in the early evening to address the serotonin dip that typically drives the late-afternoon and evening snacking that most people identify as their primary dietary challenge.

The blood sugar stability layer: everything from the blood sugar series applies here. Post-meal movement to activate GLUT4 glucose uptake and flatten the post-meal curve. Pro-metabolic carbohydrates from fruit, potatoes, root vegetables, and easily digestible starches that fill liver glycogen without producing reactive spikes. Protein at every meal to slow gastric emptying, stimulate glucagon, and provide the substrate for muscle protein synthesis. A small easily digestible carbohydrate before bed to prevent the 3am cortisol surge. Blood sugar stability is appetite stability: when glucose is regulated smoothly, the cortisol-driven hunger episodes, the energy crashes, and the urgent sugar cravings disappear because the metabolic trigger that produces them has been removed.

The muscle building layer: this is what GLP-1s don't and cannot provide, and it's the most important structural investment you can make for long-term body composition. Resistance training three to four times per week targeting the large compound movements, squats, deadlifts, presses, and rows, builds the glucose disposal infrastructure that improves insulin sensitivity around the clock and raises the metabolic rate that determines how many calories you burn at rest. Research by DeFronzo confirmed that skeletal muscle accounts for approximately 80% of insulin-stimulated glucose uptake. More muscle means better blood sugar regulation, better energy stability, and a higher resting metabolic rate, all of which support the hormonal environment where the body readily burns fat rather than defending it.

The protein imperative: this cannot be overstated in the context of any weight loss intervention. Adequate protein, specifically at least 25 to 40 grams per meal, is what prevents the muscle loss that GLP-1 drugs produce when protein intake falls due to appetite suppression. Research consistently confirms that high protein intake during caloric restriction dramatically attenuates lean mass loss. If you are eating less due to improved appetite regulation from saffron and blood sugar stability, make sure that what you are eating is anchored in protein. Eggs, meat, fish, poultry, dairy: complete animal proteins with the full amino acid profile and the zinc, B12, and iron that support hormonal health.

The pro-metabolic carbohydrate argument: this is where the Prime Choice approach diverges most clearly from the low-carb thinking that dominates weight loss culture. Severe carbohydrate restriction lowers thyroid function by reducing T4 to T3 conversion, elevates cortisol by triggering the liver glycogen depletion stress response, impairs serotonin synthesis by reducing the insulin-mediated tryptophan transport that supports serotonin production, and creates the metabolic environment where the body defends fat stores rather than releasing them. Pro-metabolic carbohydrates from whole food sources do the opposite: they keep thyroid function supported, keep cortisol low, support serotonin production, and provide the liver glycogen that prevents the stress cascade. They fill you up genuinely, from adequate cellular energy rather than from pharmacological appetite suppression, and they taste like food worth eating.

 

ABOUT PRIME CHOICE SAFFRON 

88.5mg of Crocus sativus flower extract per capsule, taken twice daily for 177mg total. This dose sits within the range used in the most clinically significant saffron research. The vegetable capsule and rice flour base make it suitable for vegans and those avoiding animal-derived capsule materials. NSF Certified and GMP Certified, manufactured in the USA, and independently lab tested for label accuracy and purity.

Saffron is one of the most expensive spices in the world by weight because harvesting the stigmas of the crocus flower is entirely manual and each flower produces only three stigmas. That cost structure means there is significant incentive in the supplement market to sell adulterated or underdosed saffron. The NSF certification on Prime Choice Saffron verifies that the extract is genuine and at the stated dose. This matters in a category where quality control failures are common.

Through Prime Choice Club's membership model you get it at up to 85% off retail. The $19.93 monthly membership includes a free product every month. Sixty servings of certified pure saffron extract at the clinical dose, at a price that makes daily use genuinely sustainable.

THE HONEST COMPARISON

GLP-1 drugs: effective appetite suppression, significant weight loss, meaningful muscle loss, significant side effect profile, $1,000 plus monthly, weight regains rapidly upon stopping, physiological dependency.

The saffron and pro-metabolic protocol: appetite regulation through serotonin support, blood sugar stabilization through dietary and supplementation strategy, body composition improvement through muscle building alongside fat loss, no muscle loss, no side effects beyond the expected, no dependency, no rebound when you stop because you've built the metabolic infrastructure that sustains the results.

The GLP-1 approach treats the symptom. The pro-metabolic approach builds the system. One produces a before-and-after photo. The other produces a different body, a different metabolism, and a different relationship with food that lasts because it's based on how your biology actually works.

I've watched this play out with clients for over two decades. The people who kept the results are the ones who built muscle, stabilized blood sugar, and addressed the serotonin and hormonal drivers of their eating patterns. The approach in this article is that approach, with a natural tool that supports the neurochemistry of appetite in a way that works with your body rather than overriding it.

REFERENCES
1. Gout B, et al. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women. Nutrition Research. 2010;30(5):305-313.
2. Mashmoul M, et al. Saffron: A Natural Potent Antioxidant as a Promising Anti-Obesity Drug. Antioxidants. 2013;2(4):293-308.
3. Akhondzadeh S, et al. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression. BMC Complementary and Alternative Medicine. 2004;4:12.
4. Hausenblas HA, et al. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. Journal of Integrative Medicine. 2013;11(6):377-383.
5. Shafiee M, et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 2010;35(5):581-588.
6. Milajerdi A, et al. The effects of saffron (Crocus sativus L.) on glycemic indices: a systematic review and meta-analysis of randomized controlled trials. Phytotherapy Research. 2019.
7. Khorasany AR, Hosseinzadeh H. Therapeutic effects of saffron (Crocus sativus L.) in digestive disorders: a review. Iranian Journal of Basic Medical Sciences. 2016;19(5):455-469.
8. Razavi BM, Hosseinzadeh H. Saffron as an antidote or a protective agent against natural or chemical toxicities. DARU Journal of Pharmaceutical Sciences. 2015.
9. Lau FC, et al. Crocin and safranal: two active compounds of saffron with anti-inflammatory and antioxidant properties. Phytomedicine. 2007.
10. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
11. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564.
12. Sodhi M, et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795-1797.
13. Bikou O, et al. Muscle loss as an adverse effect of GLP-1 receptor agonist therapy. Expert Opinion on Drug Safety. 2023.
14. Camilleri M. Gastrointestinal motility disorders and the gut microbiome. Nature Reviews Gastroenterology and Hepatology. 2021.
15. Rao SSC, Bhagatwala J. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clinical and Translational Gastroenterology. 2019;10(10):e00078.
16. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology. 2020;115(2):165-178.
17. Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its role in health and disease. Nature Reviews Gastroenterology and Hepatology. 2012;9(5):271-285.
18. Zhao L, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018;359(6380):1151-1156.
19. Krishnaswami A, et al. Aspiration risk with GLP-1 receptor agonists: guidance from the American Society of Anesthesiologists. Anesthesiology. 2023.
20. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut and Liver. 2012;6(2):172-187. (rapid weight loss and gallstone formation)
21. Faillie JL, et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Internal Medicine. 2016;176(10):1474-1484.
22. Baker JM, et al. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017;103:45-53. (estrobolome and estrogen recirculation)
23. Plottel CS, Blaser MJ. Microbiome and malignancy. Cell Host and Microbe. 2011;10(4):324-335. (beta-glucuronidase and estrogen deconjugation)
24. Sinha T, et al. The thyroid and the gut microbiome. Frontiers in Endocrinology. 2023. (gut bacteria and T4-to-T3 conversion)
13. Lixandrao ME, et al. Magnitude of muscle strength and mass adaptations between high-load and low-load resistance training: a systematic review and meta-analysis. Sports Medicine. 2018.
14. Peat R. Generative Energy. 1994. (metabolic rate, thyroid, and the importance of adequate nutrition)
15. Layman DK. Protein quantity and quality at levels above the RDA improves adult weight loss. Journal of the American College of Nutrition. 2004.
15. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009.
16. Kraemer WJ, Ratamess NA. Hormonal responses and adaptations to resistance exercise and training. Sports Medicine. 2005.
17. Blumenthal JA, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosomatic Medicine. 2007;69(7):587-596.
18. Srinivasan V, et al. Melatonin, serotonin, and the circadian system. Neurochemistry International. 2012. (serotonin and appetite regulation context)
19. Casperson SL, et al. Protein supplementation attenuates muscle loss during weight loss in obese older adults. American Journal of Clinical Nutrition. 2017.
20. Churchward-Venne TA, et al. Nutritional regulation of muscle protein synthesis with resistance exercise. Nutrition and Metabolism. 2012.

This is a sponsored advertorial for informational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article discusses GLP-1 medications for educational context only and does not constitute medical advice. If you are currently taking GLP-1 medications, do not stop or adjust your dosage without consulting your prescribing physician. Results may vary. Saffron may interact with antidepressants and other medications that affect serotonin. Consult your healthcare provider before beginning any new supplement regimen. The 14-day free trial offer requires a valid credit card and enrollment in the Prime Choice Club monthly membership program at $19.93/month after the trial period. Cancel anytime.